Safety and pharmacokinetics of SOR102, an oral bispecific inhibitor of TNF and interleukin-23 in healthy participants and patients with ulcerative colitis: a first-in-human, double-blind, randomised, placebo-controlled, phase 1 trial

DOI:10.1016/s2468-1253(25)00296-1
作者：Vipul Jairath, Silvio Danese, Geert R D’Haens, Brian G Feagan, Laurent Peyrin-Biroulet, Bruce E Sands, Ingrid Gaemers, Matt Westfall, Allyson Q Terry, Kevin J Roberts, Sara Barbat, Pamela Wedel, Jacq
文献类型：期刊论文
补充材料：只需要正文